The drugs company Imprimis Pharmaceuticals has launched a $1 (RM4.25) pill to treat Aids and cancer patients, weeks after a rival firm jacked up the cost of its tablets from $13.50 (RM57.38) to $750 (RM3187.84).
It comes as a welcome relief after the 5,500% price hike of life-saving drug Daraprim.
Martin Shkreli, chief executive of Turing Pharmaceuticals â€“ which makes Daraprim â€“ was universally criticised after the price increase.
Forbes Magazine branded him â€˜the most hated man in Americaâ€™, and critics hope and pray heâ€™s got his comeuppance.
The drug is used to treat Aids and cancer while patients are in chemotherapy, but the price went up after Shkerli acquired the patent for it.
Mark Baum, Imprimisâ€™ chief executive, said the company would be targeting drug companies that make treatments unaffordable.
He told Associated Press: “We are looking at all of these cases where the sole-source generic companies are jacking the price way up. Thereâ€™ll be many more of these.”
The Infectious Diseases Society of America (IDSA) and the HIV Medicine Association both branded the Daraprim price hike â€˜unjustifiableâ€™.
But Shkreli seems happy to remain the villain.
When US Uncut approached him for a comment, he responded with a simple yet sinister: “lol”. The nerve!
Shrkeli has amde a name for himself on social media for being a big spender who is keen on flaunting his wealth, despite possibly killing patients who couldn’t afford the ridiculous price increase.